» Articles » PMID: 32938850

Clinical Utility of the Meal Tolerance Test in the Care of Patients with Type 2 Diabetes Mellitus

Overview
Journal Intern Med
Specialty General Medicine
Date 2020 Sep 17
PMID 32938850
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Objective The measurement of C-peptide immunoreactivity (CPR) is essential for evaluating the pancreatic β-cell function and selecting appropriate therapeutic agents in patients with diabetes mellitus. The meal tolerance test (MTT) is simple to administer physiological insulin-stimulating test. Previous studies have reported that several CPR-related indices are useful markers for predicting insulin requirement in type 2 diabetes. In the present study, we investigated the serum CPR response during the MTT in hospitalized patients with type 2 diabetes mellitus in order to clarify the clinical utility of the MTT. Methods We performed the MTT using a test meal with timed measurements of the serum CPR level based on the oral glucose tolerance test over 180 minutes and tested the correlation of various CPR-related indices and clinical factors in patients with type 2 diabetes mellitus. Patients The subjects were patients with type 2 diabetes mellitus who had been admitted to our hospital for diabetes management and education. The final study population consisted of 68 patients. Results The fasting CPR level was correlated with the 24-hour urinary CPR excretion and body mass index. The serum CPR level at 120 minutes in the MTT was strongly correlated with the area under the curve of CPR during the MTT. The patients who needed insulin therapy at 6 months after hospitalization showed a significant lower incremental CPR value from 0 to 120 minutes in the MTT than those who did not need insulin therapy. Conclusion The plasma C-peptide levels at 0 and 120 minutes in the MTT provide essential information for the clinical management of patients with type 2 diabetes mellitus.

Citing Articles

Processing Alaska Pollock Protein () into Kamaboko Protein Mitigates Elevated Serum Cholesterol and Postprandial Glucose Levels in Obese Zucker Rats.

Takada N, Hosomi R, Fukunaga K Foods. 2022; 11(21).

PMID: 36360046 PMC: 9653929. DOI: 10.3390/foods11213434.

References
1.
Albareda M, Rigla M, Rodriguez-Espinosa J, Caballero A, Chico A, Cabezas R . Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2005; 68(3):202-6. DOI: 10.1016/j.diabres.2004.10.005. View

2.
Rizza R . Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes. 2010; 59(11):2697-707. PMC: 2963523. DOI: 10.2337/db10-1032. View

3.
Fujiwara D, Takahashi K, Suzuki T, Shii M, Nakashima Y, Takekawa S . Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy. J Diabetes Investig. 2014; 4(6):618-25. PMC: 4020258. DOI: 10.1111/jdi.12103. View

4.
Sonoda R, Tanaka K, Kikuchi T, Onishi Y, Takao T, Tahara T . C-Peptide Level in Fasting Plasma and Pooled Urine Predicts HbA1c after Hospitalization in Patients with Type 2 Diabetes Mellitus. PLoS One. 2016; 11(2):e0147303. PMC: 4743946. DOI: 10.1371/journal.pone.0147303. View

5.
Shankar S, Vella A, Raymond R, Staten M, Calle R, Bergman R . Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. Diabetes Care. 2016; 39(9):1602-13. PMC: 5001146. DOI: 10.2337/dc15-0931. View